Table 3.
Psychosocial and QOL measures at the time of curative radiotherapy predicting overall survival
| Predictor | Multivariate analysis | |
|---|---|---|
| HR (95% CI) | p | |
| Age, years | 0.98 (0. 89–1.07) | 0.599 |
| Biological risk | ||
| Moderate risk in Tumor 1–2 | 0.15 (0.02–0.97) | 0.047 |
| High risk in Tumor 1–2 | 0.52 (0.06–4.64) | 0.562 |
| T3 Tumor | 4.98 (0.63–39.29) | 0.127 |
| Neo-adjuvant hormonal therapy, no/yes | 0.17 (0.02–1.21) | 0.076 |
| Adjuvant hormonal therapy, no/yes | 1.54 (0.24–9.77) | 0.649 |
| Socioeconomic status | ||
| Moderate | 0.20 (0.04–0.91) | 0.037 |
| High | 0.04 (0.01–0.34) | 0.003 |
| Level of physical symptoms low, no/yesa | 9.90 (1.48–66.30) | 0.018 |
| Painb | 0.05 (0.01–0.32) | 0.002 |
| Urinary, bowel, and sexual symptoms c | 1.18 (1.03–1.36) | 0.017 |
| Fatigueb | 7.08 (1.77–28.32) | 0.006 |
HR hazard ratios in the Cox model; all variables were adjusted for each other
aBased on the RSCL Physical symptoms scale: the lowest 18.5% versus the remaining scores
bA scale in the EORTC QLQ-C30
cThe LENT-SOMA scale. When the RSCL overall quality-of-life index (1–7) was tested instead of the LENT-SOMA prostate-area symptoms, its relative HR was 0.51 (95% CI 0.27–0.95, p = 0.033)